Larimar Therapeutics, Inc. (LRMR)
2.695
-0.04
(-1.28%)
USD |
NASDAQ |
Nov 12, 16:00
2.695
0.00 (0.00%)
After-Hours: 17:57
Larimar Therapeutics Enterprise Value : 133.66M for Nov. 11, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 11, 2026 | 133.66M |
| November 10, 2026 | 129.48M |
| November 09, 2026 | 112.78M |
| November 06, 2026 | 98.17M |
| November 05, 2026 | 90.86M |
| November 04, 2026 | 136.79M |
| November 03, 2026 | 113.82M |
| November 02, 2026 | 96.08M |
| October 30, 2026 | 106.52M |
| October 29, 2026 | 127.39M |
| October 28, 2026 | 113.82M |
| October 27, 2026 | 98.17M |
| October 26, 2026 | 82.51M |
| October 23, 2026 | 93.99M |
| October 22, 2026 | 85.64M |
| October 21, 2026 | 101.30M |
| October 20, 2026 | 103.38M |
| October 19, 2026 | 69.98M |
| October 16, 2026 | 55.89M |
| October 15, 2026 | 56.41M |
| October 14, 2026 | 66.85M |
| October 13, 2026 | 74.16M |
| October 12, 2026 | 112.78M |
| October 09, 2026 | 127.39M |
| October 08, 2026 | 130.52M |
| Date | Value |
|---|---|
| October 07, 2026 | 135.74M |
| October 06, 2026 | 138.87M |
| October 05, 2026 | 147.23M |
| October 02, 2026 | 157.66M |
| October 01, 2026 | 168.10M |
| September 30, 2026 | 182.19M |
| September 29, 2026 | 176.45M |
| September 28, 2026 | 179.58M |
| September 25, 2026 | 169.67M |
| September 24, 2026 | 195.24M |
| September 23, 2026 | 252.13M |
| September 22, 2026 | 247.43M |
| September 21, 2026 | 248.48M |
| September 18, 2026 | 244.30M |
| September 17, 2026 | 245.34M |
| September 16, 2026 | 258.91M |
| September 15, 2026 | 256.83M |
| September 14, 2026 | 243.26M |
| September 11, 2026 | 257.87M |
| September 10, 2026 | 250.56M |
| September 09, 2026 | 252.65M |
| September 08, 2026 | 274.05M |
| September 04, 2026 | 248.48M |
| September 03, 2026 | 248.48M |
| September 02, 2026 | 252.65M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.270B |
| Alnylam Pharmaceuticals, Inc. | 20.81B |
| Anika Therapeutics, Inc. | 168.04M |
| Savara, Inc. | 926.34M |
| Vericel Corp. | 2.957B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.78M |
| Total Expenses (Quarterly) | 32.78M |
| EPS Diluted (Quarterly) | -0.3141 |
| Earnings Yield | -73.58% |
| Normalized Earnings Yield | -73.58 |